GC1 antibodies refer to immunoglobulins targeting specific isoforms of the GC1 protein, which exists in two distinct biological contexts: (1) Herpes simplex virus type 1 (HSV-1) glycoprotein C1 (gC1) and (2) mitochondrial glutamate carrier GC1 (SLC25A22). These antibodies enable precise detection and functional studies of their respective antigens in virology, cellular biology, and metabolic research. Below is a detailed analysis of their applications, research findings, and comparative data.
Target: HSV-1 glycoprotein C1, a surface protein critical for viral immune evasion and complement regulation.
Applications:
Serodiagnosis: Distinguishing HSV-1 from HSV-2 infections due to type-specific antibody responses .
Mechanistic Studies: Investigating gC1’s role in binding complement component C3 to evade host immunity .
Key Antibody: Mouse monoclonal antibody H633 (SeraCare), validated for immunofluorescence (IFA) and Western blot (WB) .
| Parameter | HSV-1 gC1 Antibody (H633) |
|---|---|
| Host Species | Mouse (IgG1) |
| Purity | Protein G affinity chromatography |
| Functional Activity | Reactivity at 10 µg/ml |
| Storage | -20°C (frozen) |
Target: SLC25A22, a mitochondrial transporter critical for glutamate import and cellular metabolism.
Applications:
Insulin Secretion: Studying GC1’s role in glucose-stimulated insulin release in pancreatic β-cells .
Mitochondrial Function: Analyzing glutamate transport kinetics and metabolic regulation .
Rabbit polyclonal (ab137614): Reacts with human/mouse SLC25A22; suitable for WB, IHC, ICC/IF .
Rabbit polyclonal (A306408): Validated for WB and ICC/IF; tested in knockout models .
Complement Evasion: gC1 binds human C3, inhibiting complement-mediated viral neutralization. Antibodies against gC1 block this interaction, enhancing host immune defense .
Serodiagnosis: gC1 and gG1 show 96.1% correlation in Western blot assays, enabling accurate HSV-1 detection .
Insulin Secretion: GC1 knockdown reduces glucose-stimulated insulin secretion by 23% in β-cells, restored by exogenous glutamate .
Mitochondrial Transport: GC1-specific antibodies confirm its localization to the inner mitochondrial membrane and role in glutamate/H⁺ symport .
| Feature | HSV-1 gC1 Antibody | Mitochondrial GC1 Antibody |
|---|---|---|
| Target Organism | HSV-1 | Mammalian cells |
| Primary Use | Serodiagnosis | Metabolic/molecular biology |
| Validation | IFA, WB | WB, IHC, ICC/IF |
| Cross-Reactivity | HSV-1-specific | Human/mouse/rat |
Here’s a structured FAQ collection for researchers studying GC1 Antibody, synthesized from academic literature and optimized for methodological rigor:
Discrepancies in CD4/CD8 ratios or cytokine responses (e.g., CNR vs. CR groups ) require:
Multi-parametric analysis: Combine immune cell frequencies (NKT cells, B cells), cytokine levels (IFN-γ, IL-6), and gene expression (FOXO1, SOD1) .
Longitudinal sampling: Track antibody titers pre/post-vaccination to distinguish age-related declines from transient effects .
Multiphoton microscopy: Visualize GC B-cell clonal competition (e.g., loss of 70% diversity by day 14) .
Single-cell BCR sequencing: Link somatic hypermutation rates to antibody affinity (KD < 10 nM threshold) .
Cohort stratification: Classify older adults into cytokine responders (CR) vs. non-responders (CNR) using IL-2/IL-10 ratios .
Gene expression profiling: Compare longevity-associated pathways (e.g., redox regulation, DNA repair) via RNA-seq (Table S7 ).
Phage display libraries: Screen >10⁶ variants for off-target binding to gG-2 or gD .
Surface plasmon resonance (SPR): Measure kinetic parameters (kon/koff) against gC-1 homologs .
| GC Stage | Clones Seeded | Clones Retained (Day 14) | Affinity (KD, nM) | Source |
|---|---|---|---|---|
| Early | 200 | 60 | 85 ± 12 | |
| Late | 150 | 18 | 9.7 ± 2.1 |